Genfit SA (XUP.DU)
- GlobeNewswire
GENFIT Announces Revenues and Cash Position as of December 31, 2022
Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022. Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its cash position as of December 31, 2022 and revenues for 2022. 1 2 Financials As of December 3
- InvestorPlace
The 7 Best Biotech Stocks to Buy for February 2023
While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy. By that, I mean biotechnology firms may enjoy some economic insulation as their relevance supersedes variables like interest rate dynamics. Still, it doesn’t mean that the best biotech stocks to buy are immune from
- GlobeNewswire
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 30, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the
